Literature DB >> 34519877

Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications.

Roberta Catania1,2, Kalina Chupetlovska3,4, Amir A Borhani5,4, Ekta Maheshwari4, Alessandro Furlan4.   

Abstract

Vascular invasion by hepatocellular carcinoma (HCC), also known as tumor in vein (TIV), indicates highly invasive tumor behavior and is also associated with poor outcome. Because a diagnosis of TIV precludes liver transplantation, knowledge of the imaging findings to differentiate between TIV and bland thrombus is key for proper patient management. Prior versions of liver imaging reporting and data system (LI-RADS) included presence of TIV as part of LR-5 criteria. However, even if HCC is the most common liver malignancy associated with TIV, other tumors can have vascular invasion and may occur in cirrhotic patients. For these reasons, in LI-RADS v2017 LR-TIV has been introduced as a new different diagnostic category. The aim of this article is to discuss the diagnostic criteria of LR-TIV according to LI-RADS v2018 and analyze potential pitfalls encountered on daily clinical practice. Indeterminate cases and how to manage them will also be discussed.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  CEUS; Hepatocellular carcinoma; LI-RADS; LR-TIV; Magnetic resonance imaging; Multidetector computed imaging

Mesh:

Substances:

Year:  2021        PMID: 34519877     DOI: 10.1007/s00261-021-03270-x

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  49 in total

1.  Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index.

Authors:  Gregory Y Lauwers; Benoit Terris; Ulysses J Balis; Kenneth P Batts; Jean-Marc Regimbeau; Yuchiao Chang; Fiona Graeme-Cook; Hirohiko Yamabe; Iwao Ikai; Karen R Cleary; Shiro Fujita; Jean-Francois Flejou; Lawrence R Zukerberg; David M Nagorney; Jacques Belghiti; Yoshio Yamaoka; Jean-Nicolas Vauthey
Journal:  Am J Surg Pathol       Date:  2002-01       Impact factor: 6.394

2.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

3.  Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?

Authors:  Aline Mähringer-Kunz; Verena Steinle; Christoph Düber; Arndt Weinmann; Sandra Koch; Irene Schmidtmann; Sebastian Schotten; Jan B Hinrichs; Dirk Graafen; Daniel Pinto Dos Santos; Peter R Galle; Roman Kloeckner
Journal:  Liver Int       Date:  2018-11-09       Impact factor: 5.828

Review 4.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-15       Impact factor: 11.382

5.  Direct and Indirect Economic Burden of Chronic Liver Disease in the United States.

Authors:  Maria Stepanova; Leyla De Avila; Mariam Afendy; Issah Younossi; Huong Pham; Rebecca Cable; Zobair M Younossi
Journal:  Clin Gastroenterol Hepatol       Date:  2016-07-25       Impact factor: 11.382

6.  LI-RADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease.

Authors:  Andrei S Purysko; Erick M Remer; Christopher P Coppa; Hilton M Leão Filho; Chakradhar R Thupili; Joseph C Veniero
Journal:  Radiographics       Date:  2012 Nov-Dec       Impact factor: 5.333

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 8.  Epidemiology and Management of Hepatocellular Carcinoma.

Authors:  Laura Kulik; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-10-24       Impact factor: 22.682

9.  A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma.

Authors:  Sasan Roayaie; Iris N Blume; Swan N Thung; Maria Guido; Maria-Isabel Fiel; Spiros Hiotis; Daniel M Labow; Josep M Llovet; Myron E Schwartz
Journal:  Gastroenterology       Date:  2009-06-12       Impact factor: 22.682

10.  Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B.

Authors:  Cheng Huang; Xiao-Dong Zhu; Yuan Ji; Guang-Yu Ding; Guo-Ming Shi; Ying-Hao Shen; Jian Zhou; Jia Fan; Hui-Chuan Sun
Journal:  BMC Cancer       Date:  2017-01-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.